Literature DB >> 28269771

Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.

Christelle Gervaise-Henry1, Gasshan Watfa2, Eliane Albuisson3, Allan Kolodziej1, Brigitte Dousset1, Jean-Luc Olivier1,4, Thérèse Rivasseau Jonveaux2, Catherine Malaplate-Armand1,4.   

Abstract

BACKGROUND: Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for AD diagnosis. Unfortunately, their wider use in routine and interpretation require more standardization, particularly for the pre-analytical steps. In particular, amyloid-β (Aβ)42 peptide measurement is strongly influenced by the type of collection tube and by repeated freeze/thaw cycles.
OBJECTIVE: The objectives of this study were to compare, in clinical setting, the impact of collection tubes and the repetition of freeze/thaw cycles on Aβ42 and Aβ40 concentrations and consequently determine if the Aβ42/Aβ40 ratio could resolve the diagnosis difficulties related to these pre-analytical parameters.
METHODS: CSF from 35 patients was collected in different polypropylene (PP) and stored at - 80°C after sampling. For CSF collected in the reference tube, three successive freeze-thaw cycles were done. Aβ42 and Aβ40 concentrations were determined in each condition in order to calculate the Aβ42/Aβ40 ratio.
RESULTS: Our results showed that CSF Aβ42 and Aβ40 values were significantly different according to the type of collection tube and the number of freeze/thaw cycles. Although the calculation of the Aβ42/Aβ40 ratio eliminated the effect of PP tube-dependent variation, this was not the case for freeze-thaw cycle-associated variation.
CONCLUSION: The use of Aβ42/Aβ40 ratio rather than Aβ42 alone could contribute toward pre-analytical standardization, thus allowing the general use of CSF AD biomarkers in routine practice.

Entities:  

Keywords:  Alzheimer’s disease; Aβ40 peptide; Aβ42 peptide; Aβ42/Aβ40 ratio; cerebrospinal fluid; freeze-thaw cycles; pre-analytical standardization; tube

Mesh:

Substances:

Year:  2017        PMID: 28269771     DOI: 10.3233/JAD-160865

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

1.  CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4.

Authors:  Barry D Greenberg; Corinne Pettigrew; Anja Soldan; Jiangxia Wang; Mei-Cheng Wang; Jacqueline A Darrow; Marilyn S Albert; Abhay Moghekar
Journal:  Neurology       Date:  2022-10-11       Impact factor: 11.800

2.  P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.

Authors:  Michelle R Campbell; Susan Ashrafzadeh-Kian; Ronald C Petersen; Michelle M Mielke; Jeremy A Syrjanen; Argonde C van Harten; Val J Lowe; Clifford R Jack; Joshua A Bornhorst; Alicia Algeciras-Schimnich
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-18

Review 3.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Authors:  Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk
Journal:  Alzheimers Res Ther       Date:  2019-04-22       Impact factor: 6.982

4.  Higher Level of Mismatch in APOEε4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid.

Authors:  Jonathan Vogelgsang; Ruth Vukovich; Dirk Wedekind; Jens Wiltfang
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

5.  Towards a unified protocol for handling of CSF before β-amyloid measurements.

Authors:  Shorena Janelidze; Erik Stomrud; Britta Brix; Oskar Hansson
Journal:  Alzheimers Res Ther       Date:  2019-07-19       Impact factor: 6.982

6.  Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Authors:  Daniel Alcolea; Jordi Pegueroles; Laia Muñoz; Valle Camacho; Diego López-Mora; Alejandro Fernández-León; Nathalie Le Bastard; Els Huyck; Alicia Nadal; Verónica Olmedo; Frederic Sampedro; Victor Montal; Eduard Vilaplana; Jordi Clarimón; Rafael Blesa; Juan Fortea; Alberto Lleó
Journal:  Ann Clin Transl Neurol       Date:  2019-08-28       Impact factor: 4.511

7.  Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF.

Authors:  Oskar Hansson; Sandra Rutz; Henrik Zetterberg; Ekaterina Bauer; Teresa Hähl; Ekaterina Manuilova; Mehmet Can Mert; Simone Wahl; Kaj Blennow; Erik Stomrud
Journal:  Alzheimers Dement (Amst)       Date:  2020-12-18

8.  Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.

Authors:  Inês Baldeiras; Isabel Santana; Maria João Leitão; Helena Gens; Rui Pascoal; Miguel Tábuas-Pereira; José Beato-Coelho; Diana Duro; Maria Rosário Almeida; Catarina Resende Oliveira
Journal:  Alzheimers Res Ther       Date:  2018-03-20       Impact factor: 6.982

Review 9.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

10.  Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.

Authors:  Maria João Leitão; Anuschka Silva-Spínola; Isabel Santana; Veronica Olmedo; Alicia Nadal; Nathalie Le Bastard; Inês Baldeiras
Journal:  Alzheimers Res Ther       Date:  2019-11-23       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.